The role of capecitabine in the treatment of colorectal cancer in the elderly

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2381-2386

  Pasetto, Lara Maria ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Capecitabine; Colorectal cancer; Elderly; Review

Indexed keywords

CAPECITABINE; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN;

ABDOMINAL PAIN; AGED; ALOPECIA; ANEMIA; ANOREXIA; BLISTER; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ERYTHEMA; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART EDEMA; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PARESTHESIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SKIN DISCOLORATION; SKIN TINGLING; STOMATITIS; SWELLING; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY;

EID: 33745563493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics 1999. Cancer J Clin 49: 8-31, 1999.
2. Walter LC and Corvinsky KE: Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285: 2750-2756, 2001.
3. Lichtman SM and Skirvin JA: Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 14: 1743-1755, 2000.
4. Roh M, Petrelli N, Wieand S et al: Phase III randomised trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum. Proc Am Soc Clin Oncol 20: 123a (abs 490), 2001.
5. Marsh RD, Chu NM, Vauthey JN et al: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 78(2): 217-225, 1996.
6. Streit M, Jaehde U, Stremetzne S et al: Five days continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol 8(11): 163-165, 1997.
7. Sargent DJ, Goldberg RM, Jacobson SD et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New Engl J Med 345(15): 1091-1097, 2001.
8. Van Cutsem E, Twelves C, Cassidy J et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
9. Dunst J, Teese T and Frings S: Phase I study of capecitabine combined with simultaneous radiotherapy rectal cancer. Proc Am Soc Clin Oncol 20: 149a (abs 592), 2001.
10. Yoon WH, Choi JH, Kim T et al: Enhanced tumour residual effect of preoperative chemoradiation using capecitabine for locally advanced rectal cancer. Proc Am Soc Clin Oncol 20: 104b (abs 2165), 2001.
11. Ngan S, Zalcberg J, Kell A et al: A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer. Proc Am Soc Clin Oncol 20: 149a (abs 591), 2001.
12. Dunst J, Reese T, Hoelscher T et al: Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer. Proc Am Soc Clin Oncol 22: 277 (abs 1113), 2003.
13. Kim JS, Kim JS, Cho MJ, Song KS and Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54(2): 403-408, 2002.
14. Ku JL, Yoon KA, Kim DY and Park JG: Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines. Eur J Cancer 35(12): 1724-1729, 1999.
15. Rich TA, Skivver JM, Ajani JA et al: Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32: 1025-1033, 1995.
16. Vaishampayan UN, Ben-Josef E, Philip PA et al: A single institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 53(3): 675-679, 2002.
17. Twelves C, Wong A, Nowacki MP et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26): 2746-2748, 2005.
18. Schmoll HJ, Tabernero J, Nowacli M et al: Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5FU/LV as adjuvant therapy for patients with stage III colon cancer. Proc Am Soc Clin Oncol 25: 251 (abs 3523), 2005.
19. Feliu J, Escudero P, Llosa F et al: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 23(13): 3104-3111, 2005.
20. Hoff PM, Ansari R, Batist G, Cox J et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study. J Clin Oncol 19(8): 2282-2292, 2001.
21. Cox JV, Pazdur R, Thibault A, Maroun J et al: A phase III trial of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 17: 264 (abstr 1016), 1999.
22. Twelves C: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38: 15-20, 2002.
23. Van Cutsem E, Twelves C, Cassidy J et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
24. Wellington K and Goat KL: Oral tegafur/uracil. Drugs Aging 18(12): 935-948, 2001.
25. Liu G, Franssen E, Fitch MI et al: Patients preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997.
26. Twelves CJ, Butts CA, Cassidy J et al: Capecitabine/Oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer. Post hoc analysis of a large phase II study. Clin Colorectal Cancer 5(2): 101-117, 2005.
27. Salud, Escudero P, Feliú J et al: XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 23: 276 (abs 3620), 2005.
28. Comella P, Gambardella A, Farris A et al: A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma. Southern Italy Cooperative Oncology Group trial 0108. Crit Rev Oncol Hematol 55(2): 133-139, 2005.
29. Cassidy J, Tabernero J, Twelves C et al: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11): 2084-2091, 2004.
30. Comandone A, Pochettino P, Bergnolo P et al: Capecitabine and oxaliplatin: a phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 23: 291 (abs 3681), 2005.
31. Arkenau H, Kubicka S, Greil R et al: Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim efficacy and safety analysis. Proc Am Soc Clin Oncol; Gastrointestinal Cancer Symposium 23: abs 226, 2005.
32. Fiorentini G, Dentico P, Cantore M et al: Capecitabine (XE) plus Irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer (MCRC) in elderly patients: feasibility and safety results from a phase II study. Proc Am Soc Clin Oncol 23: 289 (abs 3676), 2005.
33. Grothey A, Jordan K, Kellner O et al: Capecitabine/irinotecan (CAPIRI) and capecitabine/oxaliplatin (CAPeOX) are active second-line protocols in patients with advanced colorectal cancer after failure of first-line combination therapy: results of a randomized phase II study. Proc Am Soc Clin Oncol 23: 254 (abs 3534), 2005.
34. Patt YZ, Liebmann J, Diamandidis D et al: Capecitabine plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer: final safety findings from a phase II trial. Proc Am Soc Clin Oncol 23: 271 (abs 3602), 2005.
35. Reerink O, Mulder NH, Verschueren RC, Wiggers T, Szabo BG and Hospers GA: Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. Anticancer Res 25(1B): 629-633, 2005.
36. Rizvi AA, Schauer P, Owlia D and Kallal JE: Capecitabine-induced coronary vasospasm - a case report. Angiology 55(1): 93-97, 2004.
37. Isaacs K and Haim N: Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. J Chemother 17(3): 339-342, 2005.